Rituximab: in rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• B cells play a key role in rheumatoid arthritis (RA) pathogenesis.
• Rituximab targets CD20+ B cells, offering a potential therapeutic strategy.
• Existing RA treatments, including anti-TNF therapy, are not effective for all patients.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab in patients with active RA and inadequate response to anti-TNF therapy.
• To assess the impact of rituximab on disease activity, fatigue, quality of life, and joint structural damage.

Main Methods:

• The REFLEX trial was a 24-week, randomized, double-blind, double-dummy, international, phase III study.
• 520 patients with active RA despite methotrexate and inadequate response to anti-TNF therapy were enrolled.
• Patients received rituximab (two infusions of 1,000mg) or placebo, both with methotrexate.

Main Results:

• Rituximab plus methotrexate significantly improved all measures of disease activity, fatigue, and quality of life compared to placebo plus methotrexate.
• Long-term treatment with rituximab (up to 56 weeks) significantly inhibited joint structural damage.
• Rituximab was generally well tolerated, with manageable adverse events, primarily mild to moderate and related to the first infusion.

Conclusions:

• Rituximab is an effective treatment for patients with active RA who have an inadequate response to anti-TNF therapy.
• Rituximab demonstrates long-term efficacy in inhibiting joint structural damage and improving patient-reported outcomes.
• The safety profile of rituximab is favorable, with no change in adverse events after repeat courses.